AI-based skin cancer detection: the balance between access and overutilization

Abstract

Gregoor et al. evaluated the healthcare implications and costs of an AI-enabled mobile health app for skin cancer detection, involving 18,960 beneficiaries of a Netherlands insurer. They report a 32% increase in claims for premalignant and malignant skin lesions among app users, largely attributed to benign skin lesions and leading to higher annual costs for app users (€64.97) compared to controls (€43.09). Cost-effectiveness analysis showed a comparable cost to dermatologist-based diagnosis alone. This editorial emphasizes the balance in AI-based dermatology between increased access and increased false positives resulting in overutilization. We suggest refining the diagnostic schemas with new referral pathways to capitalize on potential savings. We also discuss the importance of econometric analysis to evaluate the adoption of new technologies, as well as adapting payment models to mitigate the risk of overutilization inherent in AI-based diagnostics such as skin cancer detection.